Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer

The androgen receptor (AR) is widely expressed in breast cancer (BC) and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown success in pre-clinical models and clinical trials of prostate cancer, and are currently being...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Ther
Hlavní autoři: Gordon, Michael A., D'Amato, Nicholas C., Gu, Haihua, Babbs, Beatrice, Wulfkuhle, Julia, Petricoin, Emanuel F., Gallagher, Isela, Dong, Ting, Torkko, Kathleen, Liu, Bolin, Elias, Anthony, Richer, Jennifer K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5517319/
https://ncbi.nlm.nih.gov/pubmed/28468774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0111
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky